655 Shares in Eli Lilly and Company $LLY Acquired by Wilian Securities LLC

Wilian Securities LLC bought a new position in shares of Eli Lilly and Company (NYSE:LLY) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 655 shares of the company’s stock, valued at approximately $704,000.

Several other large investors have also added to or reduced their stakes in the business. Cidel Asset Management Inc. grew its stake in Eli Lilly and Company by 26.5% in the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock valued at $20,392,000 after acquiring an additional 5,591 shares during the period. Spire Wealth Management lifted its holdings in shares of Eli Lilly and Company by 2.2% in the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock valued at $29,789,000 after purchasing an additional 592 shares in the last quarter. Coldstream Capital Management Inc. lifted its holdings in shares of Eli Lilly and Company by 25.6% in the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock valued at $32,365,000 after purchasing an additional 8,659 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 30.8% in the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock valued at $33,471,000 after purchasing an additional 7,338 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky lifted its holdings in shares of Eli Lilly and Company by 3.5% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 165,165 shares of the company’s stock valued at $126,022,000 after purchasing an additional 5,595 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of recent research reports. BMO Capital Markets restated an “outperform” rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a report on Thursday, February 5th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $1,285.00 target price on shares of Eli Lilly and Company in a report on Friday, March 6th. Weiss Ratings lowered Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday. HSBC lowered Eli Lilly and Company from a “hold” rating to a “reduce” rating and dropped their target price for the company from $1,070.00 to $850.00 in a report on Tuesday, March 17th. Finally, Zacks Research lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,219.26.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Retatrutide delivered highly competitive Phase 3 obesity results, with meaningful weight loss that could support a future regulatory filing and expand Lilly’s already dominant obesity portfolio.
• Positive Sentiment: Lilly said it will showcase a broad oncology pipeline at ASCO, including Retevmo, Verzenio, and new data from programs in lung, breast, and blood cancers, highlighting more than just obesity-related growth.
• Positive Sentiment: The company agreed to buy Engage Biologics for up to $202 million, adding non-viral DNA delivery technology and extending its push into genetic medicines beyond obesity.
• Positive Sentiment: Analysts and media coverage remain upbeat on Lilly’s growth story, pointing to strong demand for Mounjaro, Zepbound, and Foundayo and continued upside in the stock.
• Neutral Sentiment: Lilly also completed an $8.9 billion debt offering, which supports funding for acquisitions and R&D but may modestly increase leverage.
• Negative Sentiment: The company disclosed a lawsuit alleging a Trulicity rebate-fraud scheme that cost more than $200 million, a legal overhang that could weigh on sentiment if it develops further.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $1,041.89 on Friday. The business’s fifty day simple moving average is $941.52 and its 200 day simple moving average is $1,003.33. The firm has a market capitalization of $981.19 billion, a P/E ratio of 37.01, a price-to-earnings-growth ratio of 1.11 and a beta of 0.48. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business’s revenue was up 55.5% on a year-over-year basis. During the same period in the previous year, the company posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 35.82 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s payout ratio is presently 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.